What it is
Recursion runs one of the largest wet-lab data factories in biology, generating petabytes of cellular imaging ('phenomaps') to train models linking genes, compounds and disease. Its LOWE agentic interface orchestrates discovery workflows; it completed its acquisition of Exscientia on 20 November 2024 and released open phenomics datasets (RxRx) and molecular-ML research through Valence Labs.
Evidence trail
BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.
Model passport
How Recursion (LOWE + Phenomics) represents biology
Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.
Biological scale
Modalities & tasks
Registry, claims and frontier intelligence
Version history not yet curated
1 version record · release year not yet normalized. Model-family identity remains separate from capability and access changes.
Explore version lineage →0 normalized claims
No task, dataset, split and metric claim has been normalized for this record yet.
Open claim intelligence →0 connected frontiers
No frontier-research record currently connects to this model.
Inspect research horizon →Inputs and outputs
Inputs
Project-specific biological dataOutputs
Models, evidence or candidatesScientific and technical profile
Scientific principles
Technology
Scientific lineage
These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.
Information, entropy and communication
Claude E. ShannonSequence modelling, cross-entropy training, language models, mutual information and representation learning all use Shannon’s framework.
Rational antimetabolite drug design
Gertrude B. Elion & George H. HitchingsMechanism-based design, pathway selectivity and iterative medicinal chemistry are direct descendants of this strategy.
Hybridoma production of monoclonal antibodies
Georges J. F. Köhler & César MilsteinTherapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.
Energy-based associative neural networks
John J. HopfieldEnergy-based learning, associative retrieval and modern attention mechanisms share conceptual roots with this statistical-physics view of computation.
Evaluation evidence
BioAtlas has not yet extracted a structured benchmark claim for this record.
Known limitations
- Performance depends on the evaluation dataset and operating conditions.
- A structured benchmark claim has not yet been extracted for this record.
- Outputs require task-specific scientific and experimental validation.
Milestones
Completed the acquisition of Exscientia on 20 November 2024.
Released the open RxRx phenomics datasets.